Search Results - "KAZUNO, Hiromi"

TAS4464, A Highly Potent and Selective Inhibitor of NEDD8-Activating Enzyme, Suppresses Neddylation and Shows Antitumor Activity in Diverse Cancer Models by Yoshimura, Chihoko, Muraoka, Hiromi, Ochiiwa, Hiroaki, Tsuji, Shingo, Hashimoto, Akihiro, Kazuno, Hiromi, Nakagawa, Fumio, Komiya, Yu, Suzuki, Satoshi, Takenaka, Toru, Kumazaki, Masafumi, Fujita, Naoya, Mizutani, Takashi, Ohkubo, Shuichi

“…NEDD8-activating enzyme (NAE) is an essential E1 enzyme of the NEDD8 conjugation (neddylation) pathway, which controls cancer cell growth and survival through…”
Get full text

Discovery of Futibatinib: The First Covalent FGFR Kinase Inhibitor in Clinical Use by Ito, Satoru, Otsuki, Sachie, Ohsawa, Hirokazu, Hirano, Atsushi, Kazuno, Hideki, Yamashita, Satoshi, Egami, Kosuke, Shibata, Yoshihiro, Yamamiya, Ikuo, Yamashita, Fumiaki, Kodama, Yasuo, Funabashi, Kaoru, Kazuno, Hiromi, Komori, Toshiharu, Suzuki, Satoshi, Sootome, Hiroshi, Hirai, Hiroshi, Sagara, Takeshi

“…Deregulating fibroblast growth factor receptor (FGFR) signaling is a promising strategy for cancer therapy. Herein, we report the discovery of compound 5…”
Get full text

Possible antitumor activity of 1‐(3‐C‐ethynyl‐β‐d‐ribo‐pentofuranosyl)cytosine (ECyd, TAS‐106) against an established gemcitabine (dFdCyd)‐resistant human pancreatic cancer cell line by Kazuno, Hiromi, Sakamoto, Kazuki, Fujioka, Akio, Fukushima, Masakazu, Matsuda, Akira, Sasaki, Takuma

“…We established a variant of MIAPaCa‐2 human pancreatic cancer cells that is resistant to 2′,2′‐difluorodeoxycytidine (gemcitabine, dFdCyd), MIAPaCa‐2/dFdCyd,…”
Get full text

Sensitivity of Human Cancer Cells to the New Anticancer Ribo‐nucleoside TAS–106 Is Correlated with Expression of Uridine‐cytidine Kinase 2 by Shimamoto, Yuji, Koizumi, Katsuhisa, Okabe, Hiroyuki, Kazuno, Hiromi, Murakami, Yuko, Nakagawa, Fumio, Matsuda, Akira, Sasaki, Takuma, Fukushima, Masakazu

“…TAS–106 [l–(3–C‐ethynyl‐β‐d‐ribo‐pentofuranosyl)cytosine] is a new anticancer ribo‐nucleoside with promising antitumor activity. We have previously presented…”
Get full text

Cellular and Biochemical Mechanisms of the Resistance of Human Cancer Cells to a New Anticancer Ribo‐nucleoside, TAS‐106 by Shimamoto, Yuji, Kazuno, Hiromi, Murakami, Yuko, Azuma, Atsushi, Koizumi, Katsuhisa, Matsuda, Akira, Sasaki, Takuma, Fukushima, Masakazu

“…We have established variants of DLD‐1 human colon carcinoma and HT‐1080 human fibrosarcoma cells resistant to the new anticancer ribo‐nucleosides,…”
Get full text

Combination of pimitespib (TAS‐116) with sunitinib is an effective therapy for imatinib‐resistant gastrointestinal stromal tumors by Teranishi, Ryugo, Takahashi, Tsuyoshi, Obata, Yuuki, Nishida, Toshirou, Ohkubo, Shuichi, Kazuno, Hiromi, Saito, Yurina, Serada, Satoshi, Fujimoto, Minoru, Kurokawa, Yukinori, Saito, Takuro, Yamamoto, Kazuyoshi, Yamashita, Kotaro, Tanaka, Koji, Makino, Tomoki, Nakajima, Kiyokazu, Hirota, Seiichi, Naka, Tetsuji, Eguchi, Hidetoshi, Doki, Yuichiro

“…Despite the effectiveness of imatinib, most gastrointestinal stromal tumors (GISTs) develop resistance to the treatment, mainly due to the reactivation of KIT…”
Get full text

Repeated oral dosing of TAS-102 confers high trifluridine incorporation into DNA and sustained antitumor activity in mouse models by TANAKA, NOZOMU, SAKAMOTO, KAZUKI, OKABE, HIROYUKI, FUJIOKA, AKIO, YAMAMURA, KEISUKE, NAKAGAWA, FUMIO, NAGASE, HIDEKI, YOKOGAWA, TATSUSHI, OGUCHI, KEI, ISHIDA, KEIJI, OSADA, AKIKO, KAZUNO, HIROMI, YAMADA, YUKARI, MATSUO, KENICHI

“…TAS-102 is a novel oral nucleoside antitumor agent containing trifluridine (FTD) and tipiracil hydrochloride (TPI). The compound improves overall survival of…”
Get full text

Crucial roles of thymidine kinase 1 and deoxyUTPase in incorporating the antineoplastic nucleosides trifluridine and 2′-deoxy-5-fluorouridine into DNA by SAKAMOTO, KAZUKI, YOKOGAWA, TATSUSHI, UENO, HIROYUKI, OGUCHI, KEI, KAZUNO, HIROMI, ISHIDA, KEIJI, TANAKA, NOZOMU, OSADA, AKIKO, YAMADA, YUKARI, OKABE, HIROYUKI, MATSUO, KENICHI

“…Trifluridine (FTD) and 2′-deoxy-5-fluorouridine (FdUrd), a derivative of 5-fluorouracil (5-FU), are antitumor agents that inhibit thymidylate synthase activity…”
Get full text

Abstract C176: TAS4464, a novel, highly potent, and selective inhibitor of NEDD8 activating enzyme demonstrates sustained target inhibition and antitumor activity in a preclinical model by Yoshimura, Chihoko, Muraoka, Hiromi, Ochiiwa, Hiroaki, Tsuji, Shingo, Hashimoto, Akihiro, Takenaka, Toru, Kazuno, Hiromi, Ishida, Keiji, Mizutani, Takashi, Ohkubo, Shuichi, Matsuo, Kenichi, Utsugi, Teruhiro, Iwasawa, Yoshikazu

“…Abstract BACKGROUND: NEDD8 activating enzyme (NAE) is an essential E1 enzyme in the NEDD8 conjugation (neddylation) pathway, which controls cancer cell growth…”
Get full text

1-(3-C-Ethynyl-β-D-ribo-pentofuranosyl)cytosine (ECyd, TAS-106), a novel potent inhibitor of RNA polymerase, potentiates the cytotoxicity of CDDP in human cancer cells both in vitro and in vivo by KAZUNO, Hiromi, FUJIOKA, Akio, FUKUSHIMA, Masakazu, WATAYA, Yusuke, MATSUDA, Akira, SASAKI, Takuma

“…1-(3-C-Ethynyl-beta-D-ribo-pentofuranosyl)cytosine (ECyd, TAS-106) is a novel antitumor ribonucleoside that inhibits RNA polymerase. In the present study, we…”
Get full text

Mechanism of action of a new antitumor ribonucleoside, 1-(3 -C -ethynyl -β-D -ribo -pentofuranosyl )cytosine (ECyd, TAS-106), differs from that of 5-fluorouracil by KAZUNO, Hiromi, SHIMAMOTO, Yuji, TSUJIMOTO, Hiroaki, FUKUSHIMA, Masakazu, MATSUDA, Akira, SASAKI, Takuma

“…1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)cytosine (ECyd, TAS-106), is a new antitumor cytidine analogue, inhibiting RNA synthesis. In this study we…”
Get full text

Antitumor activity and pharmacokinetics of TAS-106, 1-(3-C-ethynyl-β-D-ribopentofuranosyl)cytosine by SHIMAMOTO, Yuji, FUJIOKA, Akio, KAZUNO, Hiromi, MURAKAMI, Yuko, OHSHIMO, Hideyuki, KATO, Toshiyuki, MATSUDA, Akira, SASAKI, Takuma, FUKUSHIMA, Masakazu

“…We examined the effects of dosage schedule on antitumor activity in vitro and in vivo to determine the optimal administration schedule for a new nucleoside…”
Get full text

Antitumor Activity and Pharmacokinetics of TAS‐106, l‐(3‐C‐Ethynyl‐β‐D‐ribo‐pentofuranosyl)cytosine by Shimamoto, Yuji, Fujioka, Akio, Kazuno, Hiromi, Murakami, Yuko, Ohshimo, Hideyuki, Kato, Toshiyuki, Matsuda, Akira, Sasaki, Takuma, Fukushima, Masakazu

“…We examined the effects of dosage schedule on antitumor activity in vitro and in vivo to determine the optimal administration schedule for a new nucleoside…”
Get full text